Exploring the underlying modes of organic nanoparticles in diagnosis, prevention, and treatment of cancer: a review from drug delivery to toxicity

被引:4
作者
Summer, Muhammad [1 ]
Hussain, Tauqeer [1 ]
Ali, Shaukat [1 ]
Khan, Rana Rashad Mahmood [2 ]
Muhammad, Gulzar [2 ]
Liaqat, Iram [3 ]
机构
[1] GC Univ Lahore, Dept Zool, Med Toxicol & Biochem Lab, Lahore 54000, Pakistan
[2] Govt Coll Univ Lahore, Fac Chem & Life Sci, Dept Chem, Lahore, Pakistan
[3] Govt Coll Univ Lahore, Dept Zool, Microbiol Lab, Lahore, Pakistan
关键词
Cancer; Nanocarriers; Nanomedicine; Theranostics; Tumor imaging; POLYMERIC MICELLES; TARGETED DELIVERY; CHITOSAN NANOPARTICLES; IN-VIVO; SURFACE MODIFICATION; CONTAINING LIPOSOMES; GOLD NANOPARTICLES; LUNG-CANCER; THERAPY; NANOTECHNOLOGY;
D O I
10.1080/00914037.2024.2375337
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Currently, the majority of cancer treatment approaches center on surgically excising cancerous tumors in addition to physical and chemical treatments like chemotherapy and radiotherapy, respectively. The main problems with these techniques are the severe adverse effects linked to systemic toxicity and suppression of normal cell development. Moreover, conventional chemotherapeutics had also severe dose-limiting side effects and were ineffective when administered systemically. Demerits of existing approaches against cancer urge the researchers to search for some alternatives like nanoparticles. Many medications can be delivered to disease areas via these nanoparticles/nanocarriers. The effective therapeutic response is limited by many biological barriers that impede the accurate transport of nanoformulations to desired locations. Most approaches to designing innovative nanocarriers with many capabilities to achieve superior therapeutics have not succeeded in bringing drug delivery systems to clinics, despite many attempts. A number of challenges still exist, including the inability of medications to be stable in nanocarriers during nonspecific distribution, circulation, and insufficient delivery of therapeutic drugs to target regions as a result of complex tumor microenvironments. This article discusses various organic nanocarriers and their promising therapeutic efficacy in the treatment of cancer. It also highlights recent advancements in stimuli-sensitive and multifunctional nanocarriers. Lastly, the difficulties and novel solutions to several hindrances and restrictions for their effective applications in the clinical procedures are also discussed in mechanisitic manner. [GRAPHICS] .
引用
收藏
页码:829 / 845
页数:17
相关论文
共 147 条
  • [51] Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions
    Ghezzi, M.
    Pescina, S.
    Padula, C.
    Santi, P.
    Del Favero, E.
    Cantu, L.
    Nicoli, S.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 332 : 312 - 336
  • [52] Polymeric micelles in cancer therapy: State of the art
    Ghosh, Balaram
    Biswas, Swati
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 332 : 127 - 147
  • [53] ENZYME-CONTAINING LIPOSOMES ALLEVIATE A MODEL FOR STORAGE DISEASE
    GREGORIADIS, G
    BUCKLAND, RA
    [J]. NATURE, 1973, 244 (5412) : 170 - 172
  • [54] Recent Advances in Design and Fabrication of Upconversion Nanoparticles and Their Safe Theranostic Applications
    Gu, Zhanjun
    Yan, Liang
    Tian, Gan
    Li, Shoujian
    Chai, Zhifang
    Zhao, Yuliang
    [J]. ADVANCED MATERIALS, 2013, 25 (28) : 3758 - 3779
  • [55] Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity
    Gubernator, Jerzy
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (05) : 565 - 580
  • [56] Tumour microenvironment responsive nanoconstructs for cancer theranostic
    Gulzar, Arif
    Xu, Jiating
    Wang, Chen
    He, Fei
    Yang, Dan
    Gai, Shili
    Yang, Piaoping
    Lin, Jun
    Jin, Dayong
    Xing, Bengang
    [J]. NANO TODAY, 2019, 26 : 16 - 56
  • [57] A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
    Hamaguchi, T.
    Kato, K.
    Yasui, H.
    Morizane, C.
    Ikeda, M.
    Ueno, H.
    Muro, K.
    Yamada, Y.
    Okusaka, T.
    Shirao, K.
    Shimada, Y.
    Nakahama, H.
    Matsumura, Y.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 170 - 176
  • [58] A toxicologic review of quantum dots: Toxicity depends on physicochemical and environmental factors
    Hardman, R
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2006, 114 (02) : 165 - 172
  • [59] Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
    Hare, Jennifer I.
    Lammers, Twan
    Ashford, Marianne B.
    Puri, Sanyogitta
    Storm, Gert
    Barry, Simon T.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2017, 108 : 25 - 38
  • [60] Control of polymeric nanoparticle size to improve therapeutic delivery
    Hickey, John W.
    Santos, Jose Luis
    Williford, John-Michael
    Mao, Hai-Quan
    [J]. JOURNAL OF CONTROLLED RELEASE, 2015, 219 : 536 - 547